CLDX
Celldex Therapeutics, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 1 ▲ Celldex Therapeutics presented positive Phase 2 open-label extension…
- Mar 27 ▲ Celldex Therapeutics presented positive Phase 2 data for barzolvolim…
- May 7 Celldex reported Q1 2026 results with a net loss of $78.7M (-$1.18/s…
- Jun 10 FDA: Celldex Announces Multiple Upcoming Presentations from Lea…
- Jun 14 ▼ Celldex reported Q1 2026 EPS of -$1.18, missing consensus of -$1.07…
- Jun 14 ▲ Celldex presented positive Phase 1 data for CDX-622, a bispecific an…
- Jun 14 FDA: Celldex Presents Positive First-in-Human Results from Phas…
- Jul 15 Leadership: Celldex Announces Planned Transition of Chief Financial Of…
- Jul 21 FDA: Celldex Reports Results from Phase 2 Study of Barzolvolima…
- Sep 22 FDA: Celldex Announces Positive Results from Phase 3 EMBARQ-CSU…
- Sep 22 ▲ Celldex reported positive topline results from its Phase 3 EMBARQ-CS…
- Sep 22 ▲ Celldex reported positive Phase 3 topline results for barzolvolimab…
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsBULLISH
Q2 2026: 32 added (2 new), 11 trimmed or exited. Largest new: Driehaus Capital Management $36.8M, Federated Hermes, $18.3M.
- AnalystsBULLISH
19 of 21 rate it Buy or better. Every target is above the price.
- EstimatesFLAT
Current-quarter EPS estimate −$0.999 → −$1.004 over 90 days. 1 up, 3 down in 30 days.
- Short sellersSTEADY
Short interest +3.5% to 9.94M shares. 10.3 days to cover, ≈12.7% of shares.
- TrendRANGE
10% below its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| BlackRock, Inc. | ADD | $260.6M |
| PRICE T ROWE ASSOCIATES INC /MD/ | DOUBLED | $174.3M |
| STATE STREET CORP | ADD | $145.1M |
| GOLDMAN SACHS GROUP INC | ADD | $60.1M |
| BAKER BROS. ADVISORS LP | ADD | $44.0M |
| DRIEHAUS CAPITAL MANAGEMENT LLC | NEW | $36.8M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | ADD | $32.1M |
| Assenagon Asset Management S.A. | DOUBLED | $29.3M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
21 analystsPrice is below the lowest target. Median implies +131%.Targets as of Nov 16, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 9, 2026 | Canaccord Genuity MAINTAIN | Buy |
| Nov 9, 2026 | Morgan Stanley MAINTAIN | Overweight |
| Oct 2, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Sep 23, 2026 | Leerink Partners MAINTAIN | Outperform |
| Sep 23, 2026 | Morgan Stanley MAINTAIN | Overweight |
| Sep 22, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
PENNER HARRY JR Director Jun 25, 2026 | AWARD | 26,000 sh |
NEIL GARRY ARTHUR Director Jun 25, 2026 | AWARD | 26,000 sh |
Cohen Cheryl Director Jun 25, 2026 | AWARD | 26,000 sh |
Torres Denice Director Jun 25, 2026 | AWARD | 26,000 sh |
Brownlie Keith L Director Jun 25, 2026 | AWARD | 26,000 sh |
MARINO JAMES J Director Jun 25, 2026 | AWARD | 26,000 sh |
Jain Rita Director Jun 25, 2026 | AWARD | 26,000 sh |
Marucci Anthony S PRESIDENT & CEO Jun 25, 2026 | AWARD | 375,000 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$1.00 | -$1.07–-$0.88 | +0.6% | $1.5M |
| Next Q | -$0.97 | -$1.14–-$0.81 | -6.7% | $250.0K |
| Current FY | -$4.05 | -$4.27–-$3.65 | +1.9% | $1.4M |
| Next FY | 🔒 Fresh data, subscribers only | |||
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
13 filings · 8 press releases · 3 bullish · 1 bearish · 2 mixed · 7 neutral- NEUTRAL SC 13G/ANov 16, 2026
Wellington Management Group LLP filed an amended Schedule 13G disclosing a 13.9% passive stake in Celldex Therapeutics as of September 30, 2026, up from 10.7% in the prior filing. The increase reflects routine portfolio rebalancing by a large asset manager and does not signal a change in…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL S-3ASRNov 5, 2026
Celldex filed an automatic shelf registration statement (S-3ASR) on November 5, 2026, registering…
This is a shelf registration only; no immediate dilution. Monitor for a prospectus supplement that would signal an actual offering. The strong cash position and positive Phase 3 data suggest any…
- NEUTRAL 8-KNov 5, 2026
Celldex reported Q3 2026 results with no material revenue and a net loss of $75.6M ($0.96 per…
The Phase 3 CSU data reported in September 2026 is the primary catalyst; watch for BLA submission timing in 2027 and topline data from Phase 2 atopic dermatitis study expected in late 2026. Cash…
- NEUTRAL INST-CLUSTERNov 3, 2026
Three small asset managers added to their CLDX positions in Q3 2026, while one larger holder…
The cluster is too small and one-sided to signal a directional thesis. The large trim by Assenagon outweighs the small adds. Monitor next 13F for whether the trimming continues or reverses.
All CLDX filing & press-release reports (21)
- SC 13G/A reportNov 16, 2026
- S-3ASR reportNov 5, 2026
- 8-K reportNov 5, 2026
- INST-CLUSTER reportNov 3, 2026
- SC 13G/A reportOct 7, 2026
- INST-CLUSTER reportSep 22, 2026
- 8-K reportSep 22, 2026
- PRESS-RELEASE reportSep 22, 2026
- PRESS-RELEASE reportJun 14, 2026
- PRESS-RELEASE reportJun 14, 2026
- INST-CLUSTER reportJun 11, 2026
- PRESS-RELEASE reportJun 10, 2026
- 8-K reportMay 7, 2026
- PRESS-RELEASE reportMay 7, 2026
- PRESS-RELEASE reportApr 6, 2026
- PRESS-RELEASE reportApr 1, 2026
- 424B5 reportApr 1, 2026
- PRESS-RELEASE reportApr 1, 2026
- PRESS-RELEASE reportMar 27, 2026
- PRESS-RELEASE reportMar 1, 2026
- INST-CLUSTER reportFeb 28, 2026